Page 2 - Sanofi India

French group Sanofi to buy US firm Principia Biopharma for $3.7 billion

PARIS (Reuters) - French healthcare company Sanofi SA has agreed to buy U.S. company Principia Biopharma Inc for around $3.7 billion, the companies said on Monday, strengthening Sanofi's presence in research and development (R&D) areas.

Nifty outlook and stock pick by HDFC Sec: Buy UltraTech Cement, Sanofi

NIfty has been forming higher tops and higher bottoms on the daily charts. Nifty is placed above 20,50,100 and 200 days moving averages, indicating bullish trend on all time frames

Sanofi India: Sturdy balance sheet, cash-generation augur well for company

High growth visibility in chronics, strong balance sheet will help sustain premium valuation

Sanofi, GSK to supply up to 60 million doses of Covid-19 vaccine to UK

Sanofi and GSK said they had reached an agreement with Britain to supply it with up to 60 million doses of a potential Covid-19 vaccine, and that discussions with other governments were ongoing

Aarti Drugs to Tata Comm: Earnings rise for 15 firms in Covid-19 economy

These companies reported an increase in revenue and/or profit before tax for the March quarter

Sanofi stops enrolling Covid-19 patients in hydroxychloroquine trials

The moves come after the World Health Organization paused its large trial of hydroxychloroquine, prompting several European governments to ban the use of the drug

From Nestle India to Maruti Suzuki, impact of Covid-19 on earning estimates

Given the huge hit from lockdown, it is not surprising that 44 of the 80 companies have seen sharp cuts ranging 10% to 72%

Double whammy: Power brands give Sanofi revenues and an edge over peers

One-time dividend of Rs 243 has given a leg up to sentiment

Market Wrap, Feb 26: Sensex ends 392 pts lower, Nifty at 11,678

Among sectoral indices, Nifty Auto index slipped the most - over 2 per cent to 7,208 levels. Nifty Metal index dropped 1.63 per cent to 2,430

Sanofi India hits record high, surges 9% on dividend of Rs 349 per share

The total dividend of Rs 343 per share includes a one-time special dividend of Rs 243 per equity share for the year ended December 31, 2019.

Nordisk and Sanofi log double-digit revenue growth in insulin pens

Around 6.98 million insulin pens were sold; it was 6.97 mn in the year-before period

Sanofi to reward shareholders with Rs 261 cr made from Ankleshwar unit sale

The sale will translate into average annual revenue loss of Rs 470 cr, which Sanofi plans to mitigate through renewed focus on core activities and brands

Sanofi: Strong domestic portfolio keeps Street positive amid pricing pain

Analysts at Elara Capital say the company's portfolio being skewed toward the high-growing chronic products, coupled with its leadership position in basal insulin, gives it an edge over its peers

Strong product mix, new launches to keep Sanofi India margins elevated

Street positive given attractive valuations; stock trading at 16x its CY20 estimates

Sanofi beats Novo to buy Ablynx for $4.8 billion in biotech M&A boom

Sanofi is already one of Ablynx's big pharma partners, after striking a deal in July 2017 to find new treatments for inflammatory diseases

Sanofi India Q2 net dips 14% at Rs 73 crore

The drug firm had posted a net profit of Rs 86.1 cr in the corresponding period of FY17

Stakeholders' body raises concerns over wilful defaulter on Sanofi's board

Proxy firm Stakeholders' Empowerment Services (SES) has raised concerns over the board composition of Sanofi India, where two former Kingfisher Airlines directors AK Ravi Nedungadi and Subash Gupte are serving as independent directors along with former RBI deputy governor Usha Thorat. "SES reiterates that there is no legal violation as far as board members are concerned. However, shareholders would be interested to know boardroom chemistry between an ex Regulator (Dr. Usha Thorat) and an ex-director of a company declared wilful defaulter," the firm said in a note ahead of the pharma major's annual general meeting on Friday. Kingfisher Airlines (KFA) has been declared as a willful defaulter by several banks after being grounded in October 2012 and its promoter Vijay Mallya is facing several proceedings including one to extradite him from UK. Nedungadi, who was a director of KFA till April 2014, had been associated with various Mallya businesses since the 1990s. Gupte, a former Air ...

Don't bring a drug under price control because it's widely sold: Shailesh Ayyangar

Interview with Managing Director, Sanofi India

Drug watchdog again finds Combiflam substandard

Yet again drug regulator finds painkiller 'sub-standard'

Drug pricing regime needs to be predictable, transparent: Sanofi

Stating the company understands its responsibility of making and distributing affordable essential medicines to all sections of society